SPTX (Seaport Therapeutics) WACC %:10.33% (As of Jun. 27, 2026)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics WACC %?

Seaport Therapeutics SPTX +10.37% 11 WACC % is 10.33% as of Jun. 27, 2026. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,428 Biotechnology companies, Seaport Therapeutics ranks worse than 55.67% on this metric.

As of today (2026-06-27), Seaport Therapeutics's weighted average cost of capital is 10.33%%. Seaport Therapeutics's ROIC % is -415.64% (calculated using TTM income statement data). Seaport Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.

For a comprehensive WACC calculation, please access the WACC Calculator.


Seaport Therapeutics  (NAS:SPTX) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Seaport Therapeutics's weighted average cost of capital is 10.33%%. Seaport Therapeutics's ROIC % is -415.64% (calculated using TTM income statement data). Seaport Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.

*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.


Related Terms

Seaport Therapeutics WACC % Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics WACC % Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
WACC %
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
WACC % 0.00 0.00

SPTX vs LXRX, DRTS, MGTX: WACC % Comparison

For the Biotechnology subindustry, Seaport Therapeutics's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seaport Therapeutics WACC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's WACC % distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's WACC % falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Seaport Therapeutics's market capitalization (E) is $1147.160 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Seaport Therapeutics's latest one-year annual average Book Value of Debt (D) is $5.0435 Mil.
a) weight of equity = E / (E + D) = 1147.160 / (1147.160 + 5.0435) = 0.9956
b) weight of debt = D / (E + D) = 5.0435 / (1147.160 + 5.0435) = 0.0044

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.376%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Seaport Therapeutics's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.376% + 1 * 6% = 10.376%

3. Cost of Debt:
GuruFocus uses latest annual Interest Expense divided by the latest one-year annual average debt to get the simplified cost of debt.
As of Dec. 2025, Seaport Therapeutics's interest expense (positive number) was $-0 Mil. Its total Book Value of Debt (D) is $5.0435 Mil.
Cost of Debt = -0 / 5.0435 = 0%.

4. Multiply by one minus annual Tax Rate:
GuruFocus uses the most recent annual Tax Expense divided by the most recent annual Pre-Tax Income to calculate the tax rate. The calculated annual tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated annual Tax Rate = 0.773 / -74.108 = -1.04%, which is less than 0%. Therefore it's set to 0%.

Seaport Therapeutics's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.9956*10.376%+0.0044*0%*(1 - 0%)
=10.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 10.33% mean?
Seaport Therapeutics (SPTX) has a WACC % of 10.33% as of Jun. 27, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #795 out of 1428 companies in the Biotechnology industry, placing it in the top 55.7%.
Is Seaport Therapeutics' WACC % too high?
Seaport Therapeutics' current WACC % is 10.33%. The Biotechnology industry median WACC % is 10.03. Seaport Therapeutics' value of 10.33% is 3% above this industry median. Based on the distribution chart, Seaport Therapeutics ranks #795 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' WACC % compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #795 out of 1428 companies for WACC %. This places Seaport Therapeutics in the lower half of its industry. The industry median WACC % is 10.03. Seaport Therapeutics' value of 10.33% is 3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Seaport Therapeutics's current WACC % of 10.33% is 3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Seaport Therapeutics and its competitors. For the Biotechnology industry, the median WACC % is 10.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seaport Therapeutics's current WACC % is 10.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current WACC % of 10.33%. The current WACC % is 10.33% and 3% above the Biotechnology industry median of 10.03. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current WACC % is 10.33% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price